JPWO2022150521A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022150521A5 JPWO2022150521A5 JP2023540927A JP2023540927A JPWO2022150521A5 JP WO2022150521 A5 JPWO2022150521 A5 JP WO2022150521A5 JP 2023540927 A JP2023540927 A JP 2023540927A JP 2023540927 A JP2023540927 A JP 2023540927A JP WO2022150521 A5 JPWO2022150521 A5 JP WO2022150521A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- substitution
- amino acid
- acid sequence
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163134412P | 2021-01-06 | 2021-01-06 | |
| US63/134,412 | 2021-01-06 | ||
| PCT/US2022/011504 WO2022150521A1 (en) | 2021-01-06 | 2022-01-06 | Anti-pd-l1 antibodies and fusion proteins thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024501771A JP2024501771A (ja) | 2024-01-15 |
| JPWO2022150521A5 true JPWO2022150521A5 (https=) | 2025-01-09 |
| JP2024501771A5 JP2024501771A5 (https=) | 2025-01-09 |
Family
ID=82357548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023540927A Pending JP2024501771A (ja) | 2021-01-06 | 2022-01-06 | 抗ｐｄ－ｌ１抗体及びその融合タンパク質 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240067729A1 (https=) |
| EP (1) | EP4274614A4 (https=) |
| JP (1) | JP2024501771A (https=) |
| KR (1) | KR20230131236A (https=) |
| CN (1) | CN116829188A (https=) |
| AU (1) | AU2022206264A1 (https=) |
| CA (1) | CA3173557A1 (https=) |
| IL (1) | IL304190A (https=) |
| MX (1) | MX2023008028A (https=) |
| WO (1) | WO2022150521A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022006492A2 (en) * | 2020-07-03 | 2022-01-06 | Palleon Pharmaceuticals Inc. | Recombinant sialidases with reduced protease sensitivity, sialidase fusion proteins, and methods of using the same |
| WO2022150516A1 (en) * | 2021-01-06 | 2022-07-14 | Palleon Pharmaceuticals Inc. | Sialidase-her2-antibody fusion proteins and methods of use thereof |
| CN120779021A (zh) * | 2024-04-08 | 2025-10-14 | 菲鹏生物股份有限公司 | 抗体缀合物及其用途 |
| WO2026037175A1 (zh) | 2024-08-16 | 2026-02-19 | 上海宝济药业股份有限公司 | 靶向靶细胞的复合物及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY148763A (en) * | 2006-03-10 | 2013-05-31 | Wyeth Corp | Anti-5t4 antibodies and uses thereof |
| AR093984A1 (es) * | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| CA2904969C (en) * | 2013-03-13 | 2025-06-17 | Imaginab, Inc. | DIFFERENTIATION CLUSTER ANTIGEN-BINDING GENETIC CONSTRUCTIONS 8 |
| CN108112254B (zh) * | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| WO2016160792A1 (en) * | 2015-03-30 | 2016-10-06 | Stcube & Co., Inc. | Antibodies specific to glycosylated pd-l1 and methods of use thereof |
| WO2018231661A1 (en) * | 2017-06-12 | 2018-12-20 | Tianxin Wang | Methods and reagents to treat tumor and cancer |
| CN115925943A (zh) * | 2017-12-27 | 2023-04-07 | 信达生物制药(苏州)有限公司 | 抗pd-l1抗体及其用途 |
| KR102914621B1 (ko) * | 2018-01-03 | 2026-01-21 | 팔레온 파마슈티칼스 인크. | 재조합 인간 시알리다제, 시알리다제 융합 단백질, 및 이를 사용하는 방법 |
| EP3569618A1 (en) * | 2018-05-19 | 2019-11-20 | Boehringer Ingelheim International GmbH | Antagonizing cd73 antibody |
| CN111606995B (zh) * | 2019-06-04 | 2021-02-12 | 优睿赛思(武汉)生物科技有限公司 | 抗人pd-l1单克隆抗体及其应用 |
| CN111763259B (zh) * | 2020-09-03 | 2020-12-15 | 北京百奥赛图基因生物技术有限公司 | 抗cd40抗体及其用途 |
-
2022
- 2022-01-06 US US18/260,364 patent/US20240067729A1/en active Pending
- 2022-01-06 KR KR1020237026702A patent/KR20230131236A/ko active Pending
- 2022-01-06 JP JP2023540927A patent/JP2024501771A/ja active Pending
- 2022-01-06 CN CN202280014778.0A patent/CN116829188A/zh active Pending
- 2022-01-06 MX MX2023008028A patent/MX2023008028A/es unknown
- 2022-01-06 WO PCT/US2022/011504 patent/WO2022150521A1/en not_active Ceased
- 2022-01-06 EP EP22737135.8A patent/EP4274614A4/en active Pending
- 2022-01-06 AU AU2022206264A patent/AU2022206264A1/en not_active Abandoned
- 2022-01-06 CA CA3173557A patent/CA3173557A1/en active Pending
-
2023
- 2023-07-02 IL IL304190A patent/IL304190A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2697257B1 (en) | Fc fusion proteins comprising novel linkers or arrangements | |
| JP2020186248A5 (https=) | ||
| EP4501957A1 (en) | Anti-serum albumin nanobody and derivative thereof | |
| CN111995681A (zh) | 抗tigit的抗体、其制备方法和应用 | |
| JP2019506140A5 (https=) | ||
| JPWO2019121906A5 (ja) | Ｐｄ－ｌｉ抗原結合部位を有するｆｃ結合断片 | |
| CN104292331A (zh) | 人源抗人α干扰素抗体及其应用 | |
| EP4524159A1 (en) | Antibody and use thereof | |
| CN114786720A (zh) | TriAx抗体的组合物及其制备和使用方法 | |
| JPWO2022150521A5 (https=) | ||
| KR20240099295A (ko) | 항-메조텔린 나노바디 및 그의 용도 | |
| JP2023550191A (ja) | Ｄｒ４および／またはｄｒ５を標的とするポリペプチドならびに関連する組成物および方法 | |
| EP4559932A1 (en) | Multispecific antibody and use thereof | |
| WO2024061224A1 (zh) | 抗her2抗体及其用途 | |
| CN119630702A (zh) | Klrb1结合剂及其使用方法 | |
| JPWO2022150507A5 (https=) | ||
| JPWO2021003469A5 (https=) | ||
| CN118620056A (zh) | Il-2变体及其用途 | |
| JPWO2022006492A5 (https=) | ||
| JP2022504392A5 (https=) | ||
| JPWO2022150516A5 (https=) | ||
| HK40121000A (en) | Anti-serum albumin nanobody and derivative thereof | |
| JP2024546726A (ja) | 抗体－サイトカイン融合タンパク質及びその用途 | |
| CN116003620A (zh) | 一种结合PD-1和Siglec15的双特异性抗体 | |
| WO2025185738A1 (zh) | 靶向cxcr3的抗原结合蛋白及其应用 |